Nicola P Klein1, Edwin Lewis2, Bruce Fireman2, Simon J Hambidge3, Allison Naleway4, Jennifer C Nelson5, Edward A Belongia6, W Katherine Yih7, James D Nordin8, Rulin C Hechter9, Eric Weintraub10, Roger Baxter2. 1. Kaiser Permanente Vaccine Study Center, Oakland, California; nicola.klein@kp.org. 2. Kaiser Permanente Vaccine Study Center, Oakland, California; 3. Kaiser Permanente Colorado Institute for Health Research, Denver and Department of Ambulatory Care Services, Denver Health, Denver, Colorado; 4. The Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon; 5. Group Health Cooperative and the University of Washington, Seattle, Washington; 6. Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Foundation, Marshfield, Wisconsin; 7. Harvard Pilgrim Health Care Institute, Boston, Massachusetts; 8. HealthPartners Research Foundation, Minneapolis, Minnesota; 9. Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California; and. 10. Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND AND OBJECTIVES: All measles-containing vaccines are associated with several types of adverse events, including seizure, fever, and immune thrombocytopenia purpura (ITP). Because the measles-mumps-rubella-varicella (MMRV) vaccine compared with the separate measles-mumps-rubella (MMR) and varicella (MMR + V) vaccine increases a toddler's risk for febrile seizures, we investigated whether MMRV is riskier than MMR + V and whether either vaccine elevates the risk for additional safety outcomes. METHODS: Study children were aged 12 to 23 months in the Vaccine Safety Datalink from 2000 to 2012. Nine study outcomes were investigated: 7 main outcomes (anaphylaxis, ITP, ataxia, arthritis, meningitis/encephalitis, acute disseminated encephalomyelitis, and Kawasaki disease), seizure, and fever. Comparing MMRV with MMR + V, relative risk was estimated by using stratified exact binomial tests. Secondary analyses examined post-MMRV or MMR + V risk versus comparison intervals; risk and comparison intervals were then contrasted for MMRV versus MMR+V. RESULTS: We evaluated 123,200 MMRV and 584,987 MMR + V doses. Comparing MMRV with MMR + V, risks for the 7 main outcomes were not significantly different. Several outcomes had few or zero postvaccination events. Comparing risk versus comparison intervals, ITP risk was higher after MMRV (odds ratio [OR]: 11.3 [95% confidence interval (CI): 1.9 to 68.2]) and MMR + V (OR: 10 [95% CI: 4.5 to 22.5]) and ataxia risk was lower after both vaccines (MMRV OR: 0.8 [95% CI: 0.5 to 1]; MMR + V OR: 0.8 [95% CI: 0.7 to 0.9]). Compared with MMR + V, MMRV increased risk of seizure and fever 7 to 10 days after vaccination. CONCLUSIONS: This study did not identify any new safety concerns comparing MMRV with MMR + V or after either the MMRV or the MMR + V vaccine. This study provides reassurance that these outcomes are unlikely after either vaccine.
BACKGROUND AND OBJECTIVES: All measles-containing vaccines are associated with several types of adverse events, including seizure, fever, and immune thrombocytopenia purpura (ITP). Because the measles-mumps-rubella-varicella (MMRV) vaccine compared with the separate measles-mumps-rubella (MMR) and varicella (MMR + V) vaccine increases a toddler's risk for febrile seizures, we investigated whether MMRV is riskier than MMR + V and whether either vaccine elevates the risk for additional safety outcomes. METHODS: Study children were aged 12 to 23 months in the Vaccine Safety Datalink from 2000 to 2012. Nine study outcomes were investigated: 7 main outcomes (anaphylaxis, ITP, ataxia, arthritis, meningitis/encephalitis, acute disseminated encephalomyelitis, and Kawasaki disease), seizure, and fever. Comparing MMRV with MMR + V, relative risk was estimated by using stratified exact binomial tests. Secondary analyses examined post-MMRV or MMR + V risk versus comparison intervals; risk and comparison intervals were then contrasted for MMRV versus MMR+V. RESULTS: We evaluated 123,200 MMRV and 584,987 MMR + V doses. Comparing MMRV with MMR + V, risks for the 7 main outcomes were not significantly different. Several outcomes had few or zero postvaccination events. Comparing risk versus comparison intervals, ITP risk was higher after MMRV (odds ratio [OR]: 11.3 [95% confidence interval (CI): 1.9 to 68.2]) and MMR + V (OR: 10 [95% CI: 4.5 to 22.5]) and ataxia risk was lower after both vaccines (MMRV OR: 0.8 [95% CI: 0.5 to 1]; MMR + V OR: 0.8 [95% CI: 0.7 to 0.9]). Compared with MMR + V, MMRV increased risk of seizure and fever 7 to 10 days after vaccination. CONCLUSIONS: This study did not identify any new safety concerns comparing MMRV with MMR + V or after either the MMRV or the MMR + V vaccine. This study provides reassurance that these outcomes are unlikely after either vaccine.
Authors: Douglas J Opel; Matthew P Kronman; Douglas S Diekema; Edgar K Marcuse; Jeffrey S Duchin; Eric Kodish Journal: Pediatrics Date: 2016-03-18 Impact factor: 7.124
Authors: T J Martin; M Fahey; M Easton; H J Clothier; R Samuel; N W Crawford; J P Buttery Journal: Hum Vaccin Immunother Date: 2021-04-09 Impact factor: 3.452
Authors: Joshua R Francis; Peter Richmond; Christine Robins; Katie Lindsay; Avram Levy; Paul V Effler; Meredith Borland; Christopher C Blyth Journal: BMC Pediatr Date: 2016-12-03 Impact factor: 2.125
Authors: Michał Konrad Zarobkiewicz; Aleksandra Zimecka; Tomasz Zuzak; Dominika Cieślak; Jacek Roliński; Ewelina Grywalska Journal: Hum Vaccin Immunother Date: 2017-09-21 Impact factor: 3.452